National Sleep Foundation (NSF) Statement on the Approval of Lunesta (TM) (Eszopiclone)
WASHINGTON, Dec. 16 /PRNewswire/ -- The Food and Drug Administration's (FDA) approval today of Lunesta(TM) (eszopiclone) for the treatment of insomnia coincides with a growing medical and scientific interest in this condition. Symptoms of insomnia are extraordinarily common. More than one-half of America's adults, 58% or 126 million people, experience at least one symptom of insomnia a few nights a week, according to NSF's 2002 Sleep in America poll. Insomnia is more prevalent among older adults and women. It is a frequent problem for individuals with a variety of medical and psychiatric conditions, and in shift workers. Insomnia can be primary (not associated with another medical condition or disease), but is often associated with other health problems or disease including pain, depression, heart disease and sleep disorders such as obstructive sleep apnea and restless legs syndrome. Insomnia can also be caused by certain medications and lifestyle factors. If insomnia persists, a physician should be consulted to ensure that the sleep problem is not due to another disease and to ensure that it does not become conditioned or habitual. Chronic insomnia may be associated with impaired cognitive functions such as memory and concentration, a higher risk of mental health problems, safety and occupational concerns, and reduced quality of life. Insomnia treatment includes the recommendation to adhere to the principles of good sleep hygiene, including behavioral practices such as reducing caffeine in the diet and establishing standard bedtimes. Healthcare professionals may treat insomnia by behavioral and cognitive methods that promote relaxation, increase the amount of bedtime actually spent sleeping, and address maladaptive sleep expectations and attitudes like "I'll never fall asleep." Pharmacotherapy, including use of hypnotic medications that reduce time to fall asleep, increase total sleep time, reduce awakenings, and improve sleep quality may be prescribed. Based on published clinical reports, Lunesta(TM) is the first pharmacological treatment that has demonstrated safety and efficacy of long- term nightly use. According to Thomas Roth, PhD, a sleep researcher at the Henry Ford Hospital, Detroit, "Lunesta(TM) helps patients fall asleep and stay asleep throughout the night." Comprehensive information about getting sufficient sleep, insomnia and sleep disorders tailored to different age groups, genders and lifestyles can be found at http://www.sleepfoundation.org. The National Sleep Foundation is an independent nonprofit organization dedicated to improving public health and safety by achieving understanding of sleep and sleep disorders, and by supporting education, sleep-related research and advocacy. Contact: Marcia C. Stein (202) 347-3471 x205 Mstein@sleepfoundation.org
SOURCE National Sleep Foundation
More by this Source
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.